SciClone Pharmaceuticals, Inc. And Sigma-Tau Pharmaceuticals Report Promising Interim Phase 2 Results In Advanced-Stage Malignant Melanoma Trial
SAN MATEO, CA -- (MARKET WIRE) -- 12/14/2005 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and Sigma-Tau S.p.A today announced promising interim results from a large phase 2 clinical trial evaluating ZADAXIN® (thymalfasin) in combination with dacarbazine (DTIC) chemotherapy with and without low-dose interferon alpha to treat patients with stage IV, the most advanced and imminently fatal form of, malignant melanoma. These preliminary data, provided by Sigma-Tau, show a distinct ZADAXIN dose-dependent response in combination with DTIC chemotherapy with and without low-dose interferon alpha. SciClone will host a conference call at 9:00 a.m. ET today to review these clinical data.